Cellectar Biosciences, Inc. (CLRB) - Q1 2026 10-Q Summary
Business Context and Reporting Period
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company developing cancer treatments using its proprietary Phospholipid Drug Conjugate (PDC) platform. The primary asset is iopofosine I 131 (CLR 131), a radioconjugate for Waldenstrom macroglobulinemia (WM) and other malignancies. This report covers the quarterly period ended March 31, 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(5,653,946) | $(6,604,029) |
| Net Loss Per Share (Basic/Diluted) | $(1.33) | $(4.30) |
| Cash and Cash Equivalents (End of Period) | $8,347,090 | $13,905,173 |
| Cash Used in Operating Activities | $(4,845,565) | $(9,383,434) |
| Total Assets | $11,119,761 | $14,978,321 |
| Accumulated Deficit | $(274,787,446) | $(253,946,492) |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $950,000 (14%) compared to Q1 2025, driven by a $717,000 swing in warrant valuation (from a $340k loss to a $77k gain) and reduced operating expenses.
- Operating Expenses: Total operating expenses declined to $5.79 million from $6.40 million.
- R&D: Decreased by $420,000 (12%) due to lower clinical project costs (WM enrollment concluded) and pre-clinical costs, partially offset by a $536,000 increase in manufacturing costs.
- G&A: Decreased by $187,000 (6%) primarily due to reduced personnel costs.
- Liquidity: Cash balance decreased by approximately $4.85 million during the quarter. The company reported a cash burn rate that limits operations to the second quarter of 2027 without additional funding.
- Warrant Liability: The fair value of liability-classified warrants decreased from $226,000 to $149,000, resulting in a non-cash gain of $77,000.
Guidance, Outlook, and Risks
- Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern. Management plans to secure additional capital via equity/debt sales or strategic transactions. Without further action, operations may cease by Q2 2027.
- Recent Financing (Subsequent Event): On May 5, 2026, the company entered into agreements to raise approximately $35 million upfront and up to $105 million in milestone-based securities to fund a Phase 3 confirmatory study for iopofosine I 131.
- Clinical Progress:
- iopofosine I 131: Received Breakthrough Therapy Designation from the FDA for r/r WM. The CLOVER WaM Phase 2 study met its primary endpoint with a 58.2% Major Response Rate. A Phase 3 confirmatory trial is planned.
- CLR 125: Initiated a Phase 1b dose-finding study in Triple-Negative Breast Cancer (TNBC).
- Internal Controls: Management identified material weaknesses in internal control over financial reporting, specifically regarding the accounting of preferred equity, warrants, and stock-based compensation. Disclosure controls were deemed ineffective.
- Risks: Key risks include failure to secure additional funding, regulatory rejection of iopofosine I 131, and the inability to execute the Phase 3 trial.
Investor Verification Checklist
- Capital Runway: Verify the closing and terms of the May 5, 2026 financing ($35M upfront) to confirm the extension of the operating runway beyond Q2 2027.
- Phase 3 Initiation: Monitor the timeline for the initiation of the Phase 3 confirmatory trial for iopofosine I 131 in WM, which is a critical milestone for the milestone-based financing.
- Internal Control Remediation: Review future filings for progress on remediating the material weaknesses in financial reporting controls.
- Warrant Liability Volatility: Track the fair value of liability-classified warrants, as fluctuations in stock price will continue to impact reported net income/loss.
- Regulatory Feedback: Confirm the status of the FDA End-of-Phase-2 meeting outcomes and the specific design requirements for the Phase 3 trial.